<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Tioguanine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00352</strong>&#160; (APRD00290)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00352/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00352/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00352.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00352.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00352.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00352.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00352.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00352">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>2-amino-1H-purine-6(7H)-thione</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>IUPAC</td></tr><tr><td>2-aminopurine-6-thiol</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>WHO</td></tr><tr><td>Thioguanine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>USAN</td></tr><tr><td>Tioguanin</td><td>German</td><td>INN</td></tr><tr><td>Tioguanine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>BAN, DCF, BP 2011</td></tr><tr><td>Tioguaninum</td><td>Latin</td><td>INN</td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Lanvis</td><td>GlaxoSmithKline</td></tr><tr><td>Tabloid</td><td>GlaxoSmithKline</td></tr><tr><td>Tioguanina</td><td>Induquimica</td></tr><tr><td>Tioguanine</td><td>IFET</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antimetabolites-antineoplastic">Antimetabolites, Antineoplastic</a></li></ul></td></tr><tr><th>CAS number</th><td>154-42-7</td></tr><tr><th>Weight</th><td>Average: 167.192<br>Monoisotopic: 167.026565875</td></tr><tr><th>Chemical Formula</th><td>C<sub>5</sub>H<sub>5</sub>N<sub>5</sub>S</td></tr><tr><th>InChI Key</th><td>WYWHKKSPHMUBEB-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-amino-6,7-dihydro-3H-purine-6-thione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">NC1=NC(=S)C2=C(N1)N=CN2</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Imidazopyrimidines</td></tr><tr><th>Subclass</th><td>Purines and Purine Derivatives</td></tr><tr><th>Direct parent</th><td>Purinethiones</td></tr><tr><th>Alternative parents</th><td>Pyrimidinethiones; Primary Aromatic Amines; Imidazoles; Polyamines</td></tr><tr><th>Substituents</th><td>pyrimidinethione; primary aromatic amine; pyrimidine; imidazole; azole; polyamine; primary amine; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the purinethiones. These are purines in which the purine moiety bears a thioketone.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For remission induction and remission consolidation treatment of acute nonlymphocytic leukemias.</td></tr><tr><th>Pharmacodynamics</th><td>Thioguanine is an antineoplastic anti-metabolite used in the treatment of several forms of leukemia including acute nonlymphocytic leukemia. Anti-metabolites masquerade as purine or pyrimidine - which become the building blocks of DNA. They prevent these substances becoming incorporated in to DNA during the "S" phase (of the cell cycle), stopping normal development and division. Thioguanine was first synthesized and entered into clinical trial more than 30 years ago. It is a 6-thiopurine analogue of the naturally occurring purine bases hypoxanthine and guanine. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Thioguanine is cross-resistant with mercaptopurine. Cytotoxicity is cell cycle phase-specific (S-phase).</td></tr><tr><th>Mechanism of action</th><td>Thioguanine competes with hypoxanthine and guanine for the enzyme hypoxanthine-guanine phosphoribosyltransferase (HGPRTase) and is itself converted to 6-thioguanilyic acid (TGMP), which reaches high intracellular concentrations at therapeutic doses. TGMP interferes with the synthesis of guanine nucleotides by its inhibition of purine biosynthesis by pseudofeedback inhibition of glutamine-5-phosphoribosylpyrophosphate amidotransferase, the first enzyme unique to the de novo pathway of purine ribonucleotide synthesis. TGMP also inhibits the conversion of inosinic acid (IMP) to xanthylic acid (XMP) by competition for the enzyme IMP dehydrogenase. Thioguanine nucleotides are incorporated into both the DNA and the RNA by phosphodiester linkages, and some studies have shown that incorporation of such false bases contributes to the cytotoxicity of thioguanine. Its tumor inhibitory properties may be due to one or more of its effects on feedback inhibition of de novo purine synthesis; inhibition of purine nucleotide interconversions; or incorporation into the DNA and RNA. The overall result of its action is a sequential blockade of the utilization and synthesis of the purine nucleotides.</td></tr><tr><th>Absorption</th><td>Absorption of an oral dose is incomplete and variable, averaging approximately 30% of the administered dose (range: 14% to 46%)</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. First converted to 6-thioguanilyic acid (TGMP). TGMP is further converted to the di- and tri-phosphates, thioguanosine diphosphate (TGDP) and thioguanosine triphosphate (TGTP) by the same enzymes that metabolize guanine nucleotides.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Tioguanine</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000077" target="_blank">Hypoxanthine-guanine phosphoribosyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET01152">Thioguanosine monophosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1310">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01152">Thioguanosine monophosphate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0000987" target="_blank">Thiopurine S-methyltransferase</a></li></ul></td><td><a href="/metabolites/DBMET01153">Methyl-thioguanosine monophosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1311">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01152">Thioguanosine monophosphate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01154">Thioguanosine diphosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1312">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01154">Thioguanosine diphosphate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01155">Thioguanosine triphosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1313">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01154">Thioguanosine diphosphate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01156">Thiodeoxyguanosine diphosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1314">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01156">Thiodeoxyguanosine diphosphate</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01157">Thiodeoxyguanosine triphosphate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1315">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>When the compound was given in singles doses of 65 to 300 mg/m^2, the median plasma half-disappearance time was 80 minutes (range 25-240 minutes)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Oral, mouse: LD<sub>50</sub> = 160 mg/kg. Symptoms of overdose include nausea, vomiting, malaise, hypotension, and diaphoresis.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td class="data-table-container"><table class="table table-condensed table-striped" id="pathways"><thead><tr><th>Pathway</th><th>Category</th></tr></thead><tbody><tr><td>Thioguanine Action Pathway</td><td>Drug action</td></tr><tr><td>Thioguanine Metabolism Pathway</td><td>Drug metabolism</td><td><a class="btn btn-default btn-xs" href="http://www.smpdb.ca/view/SMP00647?highlight%5Bcompounds%5D%5B%5D=DB00352&amp;highlight%5Bproteins%5D%5B%5D=DB00352">SMP00647</a></td></tr></tbody></table></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.8857</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.8663</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5722</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.7403</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9168</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9745</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8499</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8862</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.8332</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.7974</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.7904</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6575</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8881</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.5517</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8537</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7731
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9255
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.1583 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9743
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8918
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Glaxosmithkline</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.dsm.com">DSM Corp.</a></li>
<li><a href="http://www.gsk.com">GlaxoSmithKline Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet</td><td>Oral</td><td>40 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00233">Aminosalicylic Acid</a></td><td>Aminosalicylic acid may increase the toxicity of thiopurine, thioguanine.</td></tr><tr><td><a href="/drugs/DB01008">Busulfan</a></td><td>Busulfan increases the hepatoxicity of Thioguanine during long-term concomitant therapy. </td></tr><tr><td><a href="/drugs/DB01033">Mercaptopurine</a></td><td>Complete cross resistance may occur. </td></tr><tr><td><a href="/drugs/DB00244">Mesalazine</a></td><td>Mesalazine may increase the toxicity of thiopurine, thioguanine.</td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>The immunosuppressant, Thioguanine, may increase the adverse effects of Natalizumab. Increased risk of Progressive Multifocal Leukoencephalopathy (PML) and other infections. Concurrent therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01250">Olsalazine</a></td><td>Olsalazine may increase the toxicity of thiopurine, thioguanine.</td></tr><tr><td><a href="/drugs/DB00795">Sulfasalazine</a></td><td>Sulfasalazine may increase the toxicity of thiopurine, thioguanine.</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>